Literature DB >> 3021470

T90/44 (9.3 antigen). A cell surface molecule with a function in human T cell activation.

W Lesslauer, F Koning, T Ottenhoff, M Giphart, E Goulmy, J J van Rood.   

Abstract

T90/44 is a cell surface antigen which is present on human T cells of the helper and cytotoxic subsets and which binds the 9.3 monoclonal antibody (9.3 mAb). It is expressed in the form of 90-kDa disulfide-bonded dimers of a 44-kDa polypeptide and of free 44-kDa subunits. The function of T90/44 was investigated in a series of T cell function assays. 9.3 mAb was found to inhibit the activation of class II-restricted cloned T helper cells derived from leprosy patients and reactive with M. leprae antigens. The inhibition was first found at 1-10 ng/ml 9.3 mAb and regularly increased with the antibody concentration. The extent of the inhibition varied among different T cell clones in proportion to the respective different levels of T90/44 expression at their cell surface. The proliferative responses of peripheral blood lymphocytes (PBL) to purified protein derivative of M. tuberculosis (PPD) and tetanus toxoid were enhanced by the 9.3 mAb resulting in up to 20-30-fold increase of [3H]-thymidine incorporation. After phytohemagglutinin-induced activation of PBL, the number of T90/44 molecules per cell expressed at the cell surface rose from day 0 to day 7 by a factor of about 10. High concentrations of 9.3 mAb (5-10 micrograms/ml) at low cell densities and in the presence of monocytes in culture media supplemented by fetal calf serum were directly mitogenic for resting lymphocytes. The cytolytic effector functions of class I-restricted cytotoxic T lymphocytes (CTL) were not modulated by 9.3 mAb. The mixed lymphocyte reactions of three class I-restricted CTL to their specific target cells were found not to be significantly influenced by 9.3 mAb. In conclusion it is proposed that an antigen-independent T cell activation pathway can be entered at T90/44.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3021470     DOI: 10.1002/eji.1830161017

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  16 in total

1.  CD28 co-signaling in the adaptive immune response.

Authors:  Pavel Riha; Christopher E Rudd
Journal:  Self Nonself       Date:  2010-07-12

2.  T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1.

Authors:  P S Linsley; E A Clark; J A Ledbetter
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

Review 3.  Surface proteins and glycoproteins of human leucocytes.

Authors:  V Horejsí; V Bazil
Journal:  Biochem J       Date:  1988-07-01       Impact factor: 3.857

4.  CTLA4-Ig inhibits allergic airway inflammation by a novel CD28-independent, nitric oxide synthase-dependent mechanism.

Authors:  Christine M Deppong; Amit Parulekar; Jonathan S Boomer; Traci L Bricker; Jonathan M Green
Journal:  Eur J Immunol       Date:  2010-07       Impact factor: 5.532

5.  Purification and N-terminal amino acid sequence of the human T90/44 (CD28) antigen.

Authors:  W Lesslauer; H Gmünder; P Böhlen
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

6.  A novel T-lymphocyte molecule that may function in the induction of self-tolerance and MHC-restriction within the human thymic microenvironment.

Authors:  M Larché; J R Lamb; M A Ritter
Journal:  Immunology       Date:  1988-05       Impact factor: 7.397

7.  Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates.

Authors:  G Jung; J A Ledbetter; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

8.  Activation and expansion of tumour-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodies.

Authors:  E W Nijhuis; E vd Wiel-van Kemenade; C G Figdor; R A van Lier
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

9.  The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro.

Authors:  K Inaba; M Witmer-Pack; M Inaba; K S Hathcock; H Sakuta; M Azuma; H Yagita; K Okumura; P S Linsley; S Ikehara; S Muramatsu; R J Hodes; R M Steinman
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

Review 10.  Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma.

Authors:  J Doukas; A Rolland
Journal:  Cancer Gene Ther       Date:  2012-10-05       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.